RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-811
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_1460700; Gene model (P.falciparum): PF3D7_1247800; Gene product: dipeptidyl aminopeptidase 2 (DPAP2)
Transgene
Transgene not Plasmodium: A fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Promoter: Gene model: PBANKA_0915000; Gene model (P.falciparum): PF3D7_1133400; Gene product: apical membrane antigen 1 (ama-1)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
PhenotypeNo phenotype has been described
Last modified: 23 December 2016, 17:42
  *RMgm-811
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 25941254
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 1037m1f1mocl1 (RMgm-32)
Other information parent lineP. berghei ANKA 1037m1f1mocl1 (1037cl1; RMgm-32) is a reference ANKA mutant line which expresses GFP-luciferase under control of a schizont-specific promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 20019192).
The mutant parasite was generated by
Name PI/ResearcherJ. Lin; C.J. Janse; S.M. Khan
Name Group/DepartmentLeiden Malaria Research Group
Name InstituteLeiden University Medical Center
CityLeiden
CountryThe Netherlands
Name of the mutant parasite
RMgm numberRMgm-811
Principal name2056cl1
Alternative name∆dpap2
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteNot tested
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of DPAP2 and expresses the GFP-Luciferase fusion protein under control of the (schizont specific) ama-1 promoter.

Protein (function)
The P. falciparum and P. berghei genomes each contain three dipeptidyl aminopeptidase (dpap) homologs. P. falciparum DPAP1 and DPAP3 are critical for asexual growth. The P. falciparum dpap2 gene could be deleted. P. falciparum parasites lacking expression of (the gametocyte-specific?) DPAP2 produced normal gametocytes.

In P. berghei blood stages, dpap2 transcription is highly upregulated in gametocytes compared to asexual blood stages.

DPAP3 of P. falciparum has been implicated in egress of merozoites from the host erythrocyte.

Evidence has been presented that the P. falciparum enzyme dipeptidyl aminopeptidase 1 (DPAP1; an ortholog of the lysosomal exopeptidase cathepsin C) was located in the food/digestive vacuole and to possesses hydrolytic activity against dipeptide substrates, suggesting that DPAP1 is involved in the generation of dipeptides from hemoglobin-derived oligopeptides. The dpap1 gene could not be deleted from the P. falciparum genome, suggesting an essential role during blood stage growth/multiplication.

In P. berghei all three dpap genes can be deleted from the genome (see below).

Phenotype
Blood stages showed a normal development. The growth of asexual blood stages was slightly, but not significantly, reduced compared to wild type parasites (blood stages produced normal levels of hemozoin).

Additional information

Generation of the P. berghei mutants ∆dpap1 (RMgm-810), ∆dpap2 (RMgm-811) and ∆dpap3 (RMgm-812).
(primer sequences can either be found in Lin et al. (2015). J. Exp. Med. or obtained from the Leiden Malaria Research Group)
(A) Schematic representation of the gene-deletion constructs targeting the ORF of genes expressing dipeptidyl peptidases 1-3 (dpap1-3) by double cross-over homologous recombination and the wt gene loci before and after disruption. The constructs contain a drug-selectable marker cassette (SM; black box) and gene target regions (hatched boxes). Primer positions (arrows) for diagnostic PCRs are shown (see Table S4 for primer sequences and expected product sizes). (B) Diagnostic PCR (left, center) and RT-PCR (right) analysis confirm correct disruption of dpap1 in ∆dpap1-a. For diagnostic PCRs, the following primers were used: 5’ in, RS672/RS32; 3’ in, RS110/RS673; SM (tgdhfr/ts), RS404/RS405; dpap1 ORF, RS582/RS583. For RT-PCR the following primers were used: tub (tubulin), RS782/RS783 and dpap1, RS582/RS583. (C) Diagnostic PCR (left) and Southern analysis of pulsed field gel-separated (center) confirm correct disruption of dpap1 in ∆dpap1-b. Northern analysis of blood-stage mRNA (right) confirms the absence of dpap1 transcripts in the ∆dpap1-a mutant. The following primers were used for diagnostic PCRs: 5' integration (5’ in), L6204/L4770; 3' integration (3’ in), L4771/L6205; SM (hdfhr::yfcu), L4698/L4699; dpap1 ORF, L6206/L6207. For Southern analysis, separated chromosomes were hybridized using an hdhfr probe that recognizes the construct integrated into the dpap1 locus on chromosome 9. Northern blot was hybridized using a PCR probe recognizing the dpap1 ORF (primers L6206/L6207). As a loading control, hybridization was performed with oligonucleotide probe L644R that recognizes the large subunit rRNA. (D) Diagnostic PCR (left) and Southern analysis of pulsed field gel-separated chromosomes (center) confirms correct disruption of dpap2 in mutant ∆dpap2. Northern analysis of blood-stage mRNA (right) confirms the absence of dpap2 transcripts in the ∆dpap2 mutant. The following primers were used for diagnostic PCRs: 5’ in, L6935/L4770; 3’ in, L4771/L6936; SM (hdfhr::yfcu), L4698/L4699; dpap2 ORF, L6937/L6938. Separated chromosomes were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into dpap2 on chromosome 14, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. Northern blot was hybridized using a PCR probe recognizing the dpap2 ORF (primers L6937/L6938) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). (E) Diagnostic PCR (left) and Southern analysis of pulsed field gelseparated chromosomes (center) confirm correct disruption of dpap3 in ∆dpap3-a and ∆dpap3-b. Northern analysis of blood-stage mRNA (right) confirms the absence of dpap3 transcripts. The following primers were used for diagnostic PCRs: 5’ in, L6941/L4770; 3’ in, L4771/L6942; SM (hdfhr::yfcu), L4698/L4699; dpap3 ORF, L6943/L6944. Separated chromosomes were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into dpap3 on chromosome 10, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. Northern blot was hybridized using a PCR probe recognizing the dpap3 ORF (primers L6943/L6944) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). See Table S4 for primers used for generation of probes.

Other mutants
RMgm-810: mutant lacking expression of DPAP1
RMgm-812: mutant lacking expression of DPAP3


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_1460700
Gene Model P. falciparum ortholog PF3D7_1247800
Gene productdipeptidyl aminopeptidase 2
Gene product: Alternative nameDPAP2
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) PCR construct double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Click to view information
Click to hide information
Plasmid/construct sequence
Click to view information
Click to hide information
GAACTCGTACTCCTTGGTGACGTCGCGATTTTTGTGGGTACAATGTGGGTGTTTAGTTTT
AGTTGGTGTATTTTTATGCCAATATAAAGTACAATATTAAAAAAAAAATAATAAATTTGA
AGAATACTATGGCTTACTTACTGTAGAATATCTACACAAGTGTGGCCCATTTTAGTTTGC
TACTATTTAATGAGCAAGGAATACAACAAATATTTTATGTTAGTACTTTTGGTTGTAGAG
TGAAAAGGTGTAAAAATTCAATTTTGTGAAAATAAGGAAAATGAAAAATATATATTTTTT
TTATAAAAACTATTTTTTAAGATATAAATCATAAATAAAATATTTTATACTATATGAAAA
GAATTTTGTTTGTGTATATACAATTGATTATGATAAATGATACTTTAATATTTTAAGTTA
TACTATATTTTCCCTATAAATAAAACTAAAAAAAAAAAACATGTATATAAAGTTTACATA
AATATGAATTTCCTACAAAAAATATTTAAGTGTAATAATGAGCATAATATAATATGCACA
ATATTTTATACATAATTAAATTAGAAAGAGAAAATATATTGTATATTTATAAATTAAAAT
GTCTAAGTTATTAAAATATAACTTACATTTTTTTTCATTTATTTAATTCCAAAAAAATAA
TTGCATAGATATATATATAAAATATTTATTTGTTTATATCCGAATATTGTATTGATATTT
TGTAGTATTTAACATCCATTTTGCCTGAGCAGTGGCATTATATTTATGAGGTCGACGATG
CTTGTAGATGGCCCAGCTTAATTCTTTTCGAGCTCTTTATGCTTAAGTTTACAATTTAAT
ATTCATACTTTAAGTATTTTTTGTAGTATCCTAGATATTGTGCTTTAAATGCTCACCCCT
CAAAGCACCAGTAATATTTTCATCCACTGAAATACCATTAAATTTTCAAAAAAATACTAT
GCATATAATGTTATACATATAAACATAAAACGCCATGTAAATCAAAAAATATATAAAAAT
ATGTATAAAAATAAATATGCACTAAATATAAGCTAATTATGCATAAAAATTAAAGTGCCC
TTTATTAACTAGTCGTAATTATTTATATTTCTATGTTATAAAAAAATCCTCATATAATAA
TATAATTAATATATGTAATGTTTTTTTTATTTTATAATTTTAATATAAAATAATATGTAA
ATTAATTCAAAAAATAAATATAATTGTTGTGAAACAAAAAACGTAATTTTTTCATTTGCC
TTCAAAATTTAAATTTATTTTAATATTTCCTAAAATATATATACTTTGTGTATAAATATA
TAAAAATATATATTTGCTTATAAATAAATAAAAAATTTTATAAAACATAGGGGGATCCAT
GGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAACGG
GGACCTGCCCTGGCCACCGCTCAGGAACGAATTTAGATATTTCCAGAGAATGACCACAAC
CTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCCAT
TCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTCAA
GGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTTAC
TGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCTGT
TTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATGCA
AGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTGCC
AGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTTGA
AGTATATGAGAAGAATGATGCTAGCGGAGGAGGTGGATCTGGTGGAGGTGGAAGTGCTAG
CGTGACAGGGGGAATGGCAAGCAAGTGGGATCAGAAGGGTATGGACATTGCCTATGAGGA
GGCGGCCTTAGGTTACAAAGAGGGTGGTGTTCCTATTGGCGGATGTCTTATCAATAACAA
AGACGGAAGTGTTCTCGGTCGTGGTCACAACATGAGATTTCAAAAGGGATCCGCCACACT
ACATGGTGAGATCTCCACTTTGGAAAACTGTGGGAGATTAGAGGGCAAAGTGTACAAAGA
TACCACTTTGTATACGACGCTGTCTCCATGCGACATGTGTACAGGTGCCATCATCATGTA
TGGTATTCCACGCTGTGTTGTCGGTGAGAACGTTAATTTCAAAAGTAAGGGCGAGAAATA
TTTACAAACTAGAGGTCACGAGGTTGTTGTTGTTGACGATGAGAGGTGTAAAAAGATCAT
GAAACAATTTATCGATGAAAGACCTCAGGATTGGTTTGAAGATATTGGTGAGGCTTCGGA
ACCATTTAAGAACGTCTACTTGCTACCTCAAACAAACCAATTGCTGGGTTTGTACACCAT
CATCAGAAATAAGAATACAACTAGACCTGATTTCATTTTCTACTCCGATAGAATCATCAG
ATTGTTGGTTGAAGAAGGTTTGAACCATCTACCTGTGCAAAAGCAAATTGTGGAAACTGA
CACCAACGAAAACTTCGAAGGTGTCTCATTCATGGGTAAAATCTGTGGTGTTTCCATTGT
CAGAGCTGGTGAATCGATGGAGCAAGGATTAAGAGACTGTTGTAGGTCTGTGCGTATCGG
TAAAATTTTAATTCAAAGGGACGAGGAGACTGCTTTACCAAAGTTATTCTACGAAAAATT
ACCAGAGGATATATCTGAAAGGTATGTCTTCCTATTAGACCCAATGCTGGCCACCGGTGG
TAGTGCTATCATGGCTACAGAAGTCTTGATTAAGAGAGGTGTTAAGCCAGAGAGAATTTA
CTTCTTAAACCTAATCTGTAGTAAGGAAGGGATTGAAAAATACCATGCCGCCTTCCCAGA
GGTCAGAATTGTTACTGGTGCCCTCGACAGAGGTCTAGATGAAAACAAGTATCTAGTTCC
AGGGTTGGGTGACTTTGGTGACAGATACTACTGTGTTTAACTCGATCCCGTTTTTCTTAC
TTATATATTTATACCAATTGATTGTATTTATAACTGTAAAAATGTGTATGTTGTGTGCAT
ATTTTTTTTTGTGCATGCACATGCATGTAAATAGCTAAAATTATGAACATTTTATTTTTT
GTTCAGAAAAAAAAAACTTTACACACATAAAATGGCTAGTATGAATAGCCATATTTTATA
TAAATTAAATCCTATGAATTTATGACCATATTAAAAATTTAGATATTTATGGAACATAAT
ATGTTTGAAACAATAAGACAAAATTATTATTATTATTATTATTTTTACTGTTATAATTAT
GTTGTCTCTTCAATGATTCATAAATAGTTGGACTTGATTTTTAAAATGTTTATAATATGA
TTAGCATAGTTAAATAAAAAAAGTTGAAAAATTAAAAAAAAACATATAAACACAAATGAT
GTTTTTTCCTTCAACCTTCAATTTCGGATCCACTAGGTATTTGCGCCCTTTTTCATAAAA
CATATAAGTTCTATAAATATGTTTGCTAGTATATTATAGTGATATAGGCATATATATTAT
ATATTTATTTTTCTTACAATATAATATTAAAATTAAATAAAATTTAAATAGGATATTTAA
AATTAATAAATTAATTGTCATACATATTTCATAGATGTTATTTTGTTTTATATTATTTGG
AGTTAAAAAAAAAAAATTACCCTTTTTTGTGTTATCAAATGAATAATTAAAGGGGAAATT
GCTGCATTTTTTTTTCCATATATATATGCATATTTTGTATAAATAATTTTCTTCGGGCCA
ATGAAAAAACATGGCATTGCATTATAATATTCAGTATATGCTTTCAAAAAATGTATAAAA
TAAATATTGCAAATGGTATTTTATTTTTTTATTAATTTTTTGAAACTTAAAATAGGATAT
TTATTTTTAGCTAAAAAAGGTAGGAGGAAATTATAATTATTTTTATTTTAAAAAAATAAA
TATACATAATAAATATAAAATAAATATACAAGTGCGTATAGAGTAAACGCTAAGGGAGGT
GGTATGCTTACTGATATTTGAAGGATGGTTTATGAATAAATAAAAATAGTTTGATATTGT
GAGCAAATATACATATAAATTAATAAAAGGGAAACTGCTTTACAAAAGACTATTCTTTTC
TCTGTTTCAAAGCTAACAAGGAATAGTATATGCCACATCCAAATCATATCTACATATAGT
ATATCTGCATATAGCACATTTTAATTCGCGAGCTGAGTGTCAATGACCAACCT
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe locus was targeted using a linear construct that was generated using a 2-step, anchor tagging PCR method (for primer details see below).

The 5’- and 3’ targeting regions of the gene were PCR amplified from genomic DNA using primer pairs 1&2 and 3&4. Primers 2 and 3 have 5’-terminal extensions homologues to the hdhfr::yfcu selectable marker cassette. Primers 1 and 4 both have a 5’-terminal overhang with an anchor-tag which serves as a primer site in the 2nd PCR reaction.

The target fragments from the first PCR reaction were annealed to either side of the selectable marker cassette by PCR with anchor-tag primers 5 and 6, resulting in the 2nd PCR product. The hdhfr::yfcu selectable marker cassette used in this reaction was digested from pL0048 using restriction enzymes XhoI and NotI. pL0048 is available from The Leiden Malaria Research Group.

See for more information on the 2-step anchor tagging PCR method, the following publications:
J.W. Lin, S.M. Khan et al. A novel 'gene insertion/marker out' (GIMO) method for transgene expression and gene complementation in rodent malaria parasites PLoS One. 2011;6(12).
T. Annoura et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates Vaccine. 2012;30(16):2662-70
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1GAACTCGTACTCCTTGGTGACGTCGCGATTTTTGTGGGTACAATGTG
Additional information primer 1L6925; dpap2 5’-targeting sequence, F (NruI)
Sequence Primer 2CATCTACAAGCATCGTCGACCTCATAAATATAATGCCACTGCTC
Additional information primer 2L6926; dpap2 5’-targeting sequence, R
Sequence Primer 3CCTTCAATTTCGGATCCACTAGGTATTTGCGCCCTTTTTC
Additional information primer 3L6927; dpap2 3’-targeting sequence, F
Sequence Primer 4AGGTTGGTCATTGACACTCAGCTCGCGAATTAAAATGTGCTATATGCAG
Additional information primer 4L6928; dpap2 3’-targeting sequence, R (NruI)
Sequence Primer 5GAACTCGTACTCCTTGGTGACG
Additional information primer 5L4661; anchor tag primer
Sequence Primer 6AGGTTGGTCATTGACACTCAGC
Additional information primer 6L4662: anchor tag primer

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameA fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid KspI (SacII)
Selectable marker used to select the mutant parasitegfp (FACS)
Promoter of the selectable markerama-1
Selection (positive) procedureFACS (flowsorting)
Selection (negative) procedureNo
Additional remarks genetic modificationThe GFP-Luciferase gene (1 copy) has been inserted into the 230p locus (PB000214.00.0) by double cross-over integration.
Additional remarks selection procedureThis reporter mutant expressing GFP-Luciferase does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_0915000
Gene Model P. falciparum ortholog PF3D7_1133400
Gene productapical membrane antigen 1
Gene product: Alternative nameama-1
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4